Replimune Group Inc.

NAS: REPL

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 26, 2023, 5:06 p.m.

/zigman2/quotes/203971249/composite

$

16.28

Change

+0.32 +2.01%

Volume

Volume 6,758

Quotes are delayed by 20 min

/zigman2/quotes/203971249/composite

Previous close

$ 16.15

$ 15.96

Change

-0.19 -1.18%

Day low

Day high

$15.70

$16.64

Open

52 week low

52 week high

$15.51

$29.52

Open

Company Description

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Valuation

Price to Book Ratio

1.80

Enterprise Value to EBITDA

-3.04

Total Debt to Enterprise Value

0.12

Efficiency

Income Per Employee

-613,676.00

Liquidity

Current Ratio

17.52

Quick Ratio

17.52

Cash Ratio

17.25

Profitability

Return on Assets

-31.47

Return on Equity

-36.06

Return on Total Capital

-33.96

Return on Invested Capital

-33.11

Capital Structure

Total Debt to Total Equity

10.94

Total Debt to Total Capital

9.86

Total Debt to Total Assets

9.40

Long-Term Debt to Equity

10.27

Long-Term Debt to Total Capital

9.25

Officers and Executives

Name Age Officer Since Title
Dr. Robert Coffin 54 2015 President & Director
Mr. Philip Astley-Sparke 50 2015 Executive Chairman
Dr. Colin A. Love 62 2015 Chief Operating Officer
Mr. Konstantinos Xynos - 2022 Chief Medical Officer
Ms. Tanya N. Lewis 51 2020 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/22/2023 Pamela Esposito
Chief Business Officer
18,600   Disposition at $20.01 per share. 372,186
08/22/2023 Pamela Esposito
Chief Business Officer
5,000   Derivative/Non-derivative trans. at $15.5 per share. 77,500
08/22/2023 Pamela Esposito
Chief Business Officer
13,600   Derivative/Non-derivative trans. at $3.3 per share. 44,880
08/11/2023 Pamela Esposito
Chief Business Officer
1,400   Disposition at $20 per share. 28,000
08/11/2023 Pamela Esposito
Chief Business Officer
1,400   Derivative/Non-derivative trans. at $3.3 per share. 4,620
07/10/2023 Pamela Esposito
Chief Business Officer
2,077   Disposition at $21.12 per share. 43,866
07/10/2023 Pamela Esposito
Chief Business Officer
17,923   Disposition at $21.63 per share. 387,674
07/10/2023 Pamela Esposito
Chief Business Officer
5,000   Derivative/Non-derivative trans. at $15.5 per share. 77,500
07/10/2023 Pamela Esposito
Chief Business Officer
15,000   Derivative/Non-derivative trans. at $3.3 per share. 49,500
06/13/2023 Sushil Patel
Chief Strategy Officer
553   Disposition at $23.44 per share. 12,962
06/13/2023 Sushil Patel
Chief Strategy Officer
5,145   Disposition at $24.11 per share. 124,045
06/13/2023 Tanya N. Lewis
Chief Dev. Op. Officer
817   Disposition at $23.45 per share. 19,158
06/13/2023 Tanya N. Lewis
Chief Dev. Op. Officer
12,043   Disposition at $24.1 per share. 290,236
05/16/2023 Robert Coffin
President & Chief R&D Officer; Director
7,861   Disposition at $18.05 per share. 141,891
05/16/2023 Philip Astley-Sparke
Chief Executive Officer; Director
17,902   Disposition at $18.05 per share. 323,131
05/16/2023 Colin A. Love
Chief Operating Officer
10,775   Disposition at $18.05 per share. 194,488
05/16/2023 Pamela Esposito
Chief Business Officer
5,966   Disposition at $18.05 per share. 107,686
05/16/2023 Sushil Patel
Chief Strategy Officer
15,575   Disposition at $18.05 per share. 281,128
05/16/2023 Tanya N. Lewis
Chief Dev. Op. Officer
12,207   Disposition at $18.05 per share. 220,336
05/16/2023 Jean M. Franchi
Chief Financial Officer
11,351   Disposition at $18.05 per share. 204,885
05/16/2023 Konstantinos Xynos
Chief Medical Officer
771   Disposition at $18.05 per share. 13,916
04/01/2023 Robert Coffin
President & Chief R&D Officer; Director
45,000   Award at $0 per share. 0
04/01/2023 Philip Astley-Sparke
Chief Executive Officer; Director
142,100   Award at $0 per share. 0
04/01/2023 Colin A. Love
Chief Operating Officer
40,000   Award at $0 per share. 0
04/01/2023 Pamela Esposito
Chief Business Officer
40,000   Award at $0 per share. 0
04/01/2023 Sushil Patel
Chief Strategy Officer
40,000   Award at $0 per share. 0
04/01/2023 Tanya N. Lewis
Chief Dev. Op. Officer
40,000   Award at $0 per share. 0
04/01/2023 Jean M. Franchi
Chief Financial Officer
45,000   Award at $0 per share. 0
04/01/2023 Konstantinos Xynos
Chief Medical Officer
50,000   Award at $0 per share. 0
12/09/2022 Pamela Esposito
Chief Business Officer
15,000   Disposition at $25.03 per share. 375,450
12/09/2022 Pamela Esposito
Chief Business Officer
15,000   Derivative/Non-derivative trans. at $1.01 per share. 15,150
12/01/2022 Konstantinos Xynos
Chief Medical Officer
17,500   Award at $0 per share. 0
05/16/2022 Robert Coffin
President & Chief R&D Officer; Director
5,737   Disposition at $14.59 per share. 83,702
05/16/2022 Philip Astley-Sparke
Chief Executive Officer; Director
9,632   Disposition at $14.59 per share. 140,530
05/16/2022 Colin A. Love
Chief Operating Officer
6,324   Disposition at $14.59 per share. 92,267
05/16/2022 Pamela Esposito
Chief Business Officer
3,507   Disposition at $14.59 per share. 51,167
05/16/2022 Sushil Patel
Chief Strategy Officer
10,687   Disposition at $14.59 per share. 155,923
05/16/2022 Tanya N. Lewis
Chief Dev. Op. Officer
5,473   Disposition at $14.59 per share. 79,851
05/16/2022 Jean M. Franchi
Chief Financial Officer
3,436   Disposition at $14.59 per share. 50,131
04/01/2022 Robert Coffin
President & Chief R&D Officer; Director
26,250   Award at $0 per share. 0
04/01/2022 Philip Astley-Sparke
Chief Executive Officer; Director
70,000   Award at $0 per share. 0
04/01/2022 Colin A. Love
Chief Operating Officer
26,250   Award at $0 per share. 0
04/01/2022 Pamela Esposito
Chief Business Officer
22,750   Award at $0 per share. 0
04/01/2022 Sushil Patel
Chief Strategy Officer
52,500   Award at $0 per share. 0
04/01/2022 Tanya N. Lewis
Chief Dev. Op. Officer
52,500   Award at $0 per share. 0
04/01/2022 Jean M. Franchi
Chief Financial Officer
52,500   Award at $0 per share. 0
/news/latest/company/us/repl

MarketWatch News on REPL

  1. Novavax Inc. stock rises Wednesday, still underperforms market

    6:14 p.m. Nov. 23, 2022

    - MarketWatch Automation

  2. Novavax Inc. stock falls Tuesday, underperforms market

    6:13 p.m. Nov. 22, 2022

    - MarketWatch Automation

  3. Novavax Inc. stock falls Monday, underperforms market

    6:13 p.m. Nov. 21, 2022

    - MarketWatch Automation

  4. Novavax Inc. stock falls Friday, underperforms market

    6:13 p.m. Nov. 18, 2022

    - MarketWatch Automation

  5. Novavax Inc. stock falls Thursday, underperforms market

    6:13 p.m. Nov. 17, 2022

    - MarketWatch Automation

  6. Novavax Inc. stock underperforms Wednesday when compared to competitors

    6:13 p.m. Nov. 16, 2022

    - MarketWatch Automation

  7. Novavax Inc. stock rises Tuesday, still underperforms market

    6:13 p.m. Nov. 15, 2022

    - MarketWatch Automation

  8. Novavax Inc. stock underperforms Monday when compared to competitors

    6:13 p.m. Nov. 14, 2022

    - MarketWatch Automation

  9. Novavax Inc. stock outperforms market on strong trading day

    6:13 p.m. Feb. 11, 2022

    - MarketWatch Automation

  10. Novavax Inc. stock falls Thursday, underperforms market

    6:13 p.m. Feb. 10, 2022

    - MarketWatch Automation

  11. Novavax Inc. stock outperforms market on strong trading day

    6:13 p.m. Feb. 9, 2022

    - MarketWatch Automation

  12. Novavax Inc. stock underperforms Tuesday when compared to competitors

    6:13 p.m. Feb. 8, 2022

    - MarketWatch Automation

  13. Novavax Inc. stock outperforms market on strong trading day

    6:13 p.m. Feb. 7, 2022

    - MarketWatch Automation

  14. Novavax Inc. stock rises Friday, still underperforms market

    6:14 p.m. Feb. 4, 2022

    - MarketWatch Automation

  15. Novavax Inc. stock outperforms market despite losses on the day

    6:14 p.m. Feb. 3, 2022

    - MarketWatch Automation

  16. Novavax Inc. stock falls Wednesday, underperforms market

    6:14 p.m. Feb. 2, 2022

    - MarketWatch Automation

  17. Novavax Inc. stock rises Tuesday, outperforms market

    6:14 p.m. Feb. 1, 2022

    - MarketWatch Automation

  18. Novavax Inc. stock rises Monday, outperforms market

    6:14 p.m. Jan. 31, 2022

    - MarketWatch Automation

  19. Novavax Inc. stock outperforms market on strong trading day

    6:14 p.m. Jan. 28, 2022

    - MarketWatch Automation

  20. Novavax Inc. stock underperforms Thursday when compared to competitors

    6:14 p.m. Jan. 27, 2022

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/repl

Other News on REPL

  1. 10-K: REPLIMUNE GROUP, INC.

    8:13 a.m. May 18, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: REPLIMUNE GROUP, INC.

    9:20 a.m. Feb. 9, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: REPLIMUNE GROUP, INC.

    8:18 a.m. Nov. 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

At a Glance

Replimune Group, Inc.

500 Unicorn Park Drive

Suite 303

3rd Floor

Woburn, Massachusetts 01801

Phone

1 7812229600

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

03/2024

Revenue

N/A

Net Income

$-174.28M

Employees

284.00

/news/pressrelease/company/us/repl

Press Releases on REPL

  1. Forbion raises EUR1.35 billion across two funds

    1:00 a.m. April 19, 2023

    - GlobeNewswire

  2. Replimune to Present at Two Upcoming Investor Conferences

    9:00 a.m. March 8, 2023

    - GlobeNewswire

  3. Replimune Announces Pricing of Public Offering

    10:05 p.m. Dec. 8, 2022

    - GlobeNewswire

  4. Replimune Announces Proposed Public Offering

    5:04 p.m. Dec. 7, 2022

    - GlobeNewswire

  5. Replimune to Host Virtual Investor Event on December 7, 2022

    9:00 a.m. Nov. 22, 2022

    - GlobeNewswire

  6. Replimune to Present at Two Upcoming Investor Conferences

    4:01 p.m. Nov. 2, 2022

    - GlobeNewswire

  7. Loading more headlines...
Link to MarketWatch's Slice.